Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.

Ohad Cohen likened Medtronic's 780G to a Ferrari compared to other treatments, which he described as a donkey. • Source: Shutterstock

Medtronic has continued to publish more good news about the device it is banking on to save its fortunes in the diabetes management devices market.

What Is The 780G?

When combined with a compatible glucose monitor, Medtronic’s 780G pump creates a hybrid closed-loop system – the closest approximation of an “artificial pancreas” currently available to people with diabetes.

The glucose monitor measures blood glucose levels and the pump delivers insulin in response to current readings. Additionally, predictive algorithms estimate future blood glucose levels, ensuring more regular glycemic control.

For patients, this creates a much more hands-off experience, where manual involvement is typically only needed before a carb or sugar heavy meal.

The 780G earned a CE mark in 2020 and the company is seeking US Food and Drug Administration approval for the pairing of the 780G pump and its Guardian 4 continuous glucose monitor. (Also see "ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability" - Medtech Insight, 28 April, 2022.) 

Medtronic has been struggling to compete with Abbott and DexCom over the past three years because it does...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

More from R&D

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.